Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | LATS2 |
| Gene Name: | LATS2 |
| Protein Full Name: | Serine/threonine-protein kinase LATS2 |
| Alias: | EC 2.7.11.1 |
| Mass (Da): | 120194 |
| Number AA: | 1088 |
| UniProt ID: | Q9NRM7 |
| Locus ID: | 26524 |
| COSMIC ID: | LATS2 |
| Gene location on chromosome: | 13q12.11 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 20473 |
| Percent of cancer specimens with mutations: | 0.87 |
| Gene undergoes hypermethylation: | Astrocytomas, Acute lymphoblastic leukaemia, various cancers. Promoter hypermethylation. |
| Normal role description: | LATS2 is protein-serine/threonine kinase involved in cell-cycle regulation and spindle formation. LATS2 is localized to centrosomes during interphase to late metaphase by aurora-A kinase. LATS2 recruits gamma-tubulin for spindle formation. LATS2 may inhibit cell growth during arrest at the G1/S or G2/M check points. LATS2 appears to function primarily as a tumour suppressor protein through activating p53 by physically inhibiting MDM2. Through a positive feedback mechanism p53 can positively regulate expression of LATS2. Abberant expression of LATS2 either through downregulation or hypermethylation has been observed in various cancers including, lung, breast, hepatocellular, leukaemias, testicular, astrocytomas, retinoblastoma and head and neck cancers. |